Synchronous primary breast invasive carcinoma and breast metastasis from high-grade serous ovarian carcinoma: a case report and literature review
Frontiers in Oncology · 17.06.2026 · 16
DOI: 10.3389/fonc.2026.1790056 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 17.06.2026. Verfasst von Jingge Miao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Yunnan Key Laboratory of Breast Cancer Precision Medicine, Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University,…. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Breast metastasis from high-grade serous ovarian carcinoma is rare, and its coexistence with a synchronous primary breast carcinoma is exceptionally uncommon. Distinguishing metastatic ovarian carcinoma from primary breast carcinoma is clinically important because treatment strategies and prognosis differ substantially. Case presentation We report a 48-year-old premenopausal woman who presented with pleural effusion, abdominal distension, bilateral adnexal masses, multiple breast nodules, and systemic lymphadenopathy. Pathological examination of the pelvic lesion supported high-grade serous carcinoma, whereas breast biopsy demonstrated two morphologically distinct adenocarcinoma components. Immunohistochemical profiling, including breast-lineage markers and Müllerian/ovarian markers, supported the coexistence of primary breast invasive carcinoma and metastatic ovarian carcinoma involving the breast. Intervention and outcome The patient was diagnosed with FIGO stage IVB high-grade serous ovarian carcinoma with breast, pleural, peritoneal, and lymph node involvement, synchronous with primary breast carcinoma. She received neoadjuvant paclitaxel plus carboplatin and achieved a partial response, followed by interval cytoreductive surgery, additional chemotherapy combined with bevacizumab, breast tumor excision, and maintenance therapy with fluzoparib plus bevacizumab. At the last follow-up on December 20, 2025, no evidence of disease progression was observed.
Conclusion
This case highlights the diagnostic difficulty of breast lesions in patients with ovarian carcinoma. Morphology combined with an appropriate immunohistochemical panel is essential for distinguishing primary breast carcinoma from metastatic ovarian carcinoma. Multidisciplinary evaluation and genetic assessment should be considered in similar cases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Yunnan Key Laboratory of Breast Cancer Precision Medicine, Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kun…
- Department of Breast Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Zitieren
APA
Miao, J., Liu, N., Gong, F., Chen, J., Wang, C., Lin, M., Li, N., Chen, Y., Ge, F., & Chen, W. (2026). Synchronous primary breast invasive carcinoma and breast metastasis from high-grade serous ovarian carcinoma: a case report and literature review. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1790056
Vancouver
Miao J, Liu N, Gong F, Chen J, Wang C, Lin M, et al. Synchronous primary breast invasive carcinoma and breast metastasis from high-grade serous ovarian carcinoma: a case report and literature review. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1790056
BibTeX
@article{Miao2026,
author = {Miao, Jingge and Liu, Nianqiu and Gong, Fuhong and Chen, Jiayi and Wang, Chenxi and Lin, Mengping and Li, Na and Chen, Yilin and Ge, Fei and Chen, Wenlin},
title = {Synchronous primary breast invasive carcinoma and breast metastasis from high-grade serous ovarian carcinoma: a case report and literature review},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1790056}
}
EUVIMED